Colorectal cancer (CRC) globally represents a significant source of illness and death related to cancer. Even though there is proof of a 90% 5-year survival rate with early-stage diagnosis, fewer than 40% of cases are identified at a localized stage. Despite recent progress in surgical and multimodal therapies, the overall survival rate for advanced CRC patients remains markedly low, it has become possible to develop biomarkers that help with the identification of patient responses for cancer diagnosis, management, and surveillance. Hence, CEA and CA19.9 biomarkers underwent testing in a patient sample to assess their respective effectiveness, and their p-values were measured, we observed a statistically significant p-value of 0.049 for CEA, indicating its significance. In contrast, CA19.9 yielded a p-value of 0.084, which is considered not statistically significant, CEA and CA19.9 exhibit a positive correlation with a coefficient of 0.403. And the P-value is statistically significant at 0.001.